Project Grant K99CA307323
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $162K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded $421,825 to The General Hospital Corporation (Massachusetts General Hospital) on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an improved fibrin-targeted radiopharmaceutical for gastric cancer treatment. The project addresses advanced gastric cancer, for which chemotherapy remains the standard treatment but nearly all patients eventually relapse or experience disease progression. The...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $162,608 under the Cancer Treatment Research program (CFDA 93.395) on August 14, 2026. The award funds an exploratory research project characterizing how moderate-dose external radiotherapy enhances blood perfusion in hepatocellular carcinoma tumors, with the goal of optimizing combination strategies between ionizing radiation and perfusion-driven therapies. The research involves irradiating a...
- The National Cancer Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $682,561 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a non-invasive molecular magnetic resonance imaging biomarker for early detection of pancreatic ductal adenocarcinoma. The research will develop secretagogue-stimulated zinc-secretion MRI (SSZS-MRI), which measures transient hormone-evoked extracellular zinc...
- The National Cancer Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $161,460 under the Cancer Research Manpower program (CFDA 93.398) on June 1, 2026, to develop quantitative predictive dosimetry for transarterial radioembolization (TARE) in hepatocellular carcinoma treatment. The funded research will design a novel quantitative TARE dosimetry framework capable of predicting realistic yttrium-90 dose distributions to tumor tissue while...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $659,201 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on the integrated stress response in glioblastoma pathogenesis and response to therapy. The funded research investigates how glioma stem cells survive and proliferate within the hostile glioblastoma microenvironment through adaptive stress response mechanisms. The work focuses on the...
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- The National Institute of General Medical Sciences awarded The General Hospital Corporation (Massachusetts General Hospital) $453,750 under the Biomedical Research and Research Training program (CFDA 93.859) on August 1, 2026, through Project Grant R35GM165865. The award funds research investigating how mitochondrial metabolism regulates species-specific developmental rates in mammalian embryos. The research program uses an in vitro system that recapitulates the two- to threefold difference in...
- The National Cancer Institute awarded Massachusetts Institute of Technology $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to investigate how phospholipase genetic variants in pancreatic cancer drive immune evasion and immunotherapy resistance. The recipient will conduct cellular, molecular, and biochemical experiments to determine the mechanism by which mutations in the PLCG1 and PLCG2 genes mediate immune evasion across different cell types (Aim 1),...